EXEL - Exelixis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.55
-0.85 (-3.97%)
At close: 4:00PM EDT

20.55 0.00 (0.00%)
After hours: 4:24PM EDT

Stock chart is not supported by your current browser
Previous Close21.40
Open21.46
Bid20.50 x 1400
Ask20.57 x 3100
Day's Range20.52 - 21.48
52 Week Range13.42 - 25.31
Volume5,142,563
Avg. Volume3,392,762
Market Cap6.193B
Beta (3Y Monthly)2.17
PE Ratio (TTM)9.30
EPS (TTM)2.21
Earnings DateMay 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.00
Trade prices are not sourced from all markets
  • Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
    Zacks8 hours ago

    Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

    Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Kidney-Cancer Market: Good for Patients, Hard for Investors
    Motley Foolyesterday

    Kidney-Cancer Market: Good for Patients, Hard for Investors

    Drugmakers battle for patients.

  • Did Hedge Funds Drop The Ball On Exelixis, Inc. (EXEL) ?
    Insider Monkey3 days ago

    Did Hedge Funds Drop The Ball On Exelixis, Inc. (EXEL) ?

    Does Exelixis, Inc. (NASDAQ:EXEL) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]

  • 3 Cancer Treatment Stocks to Buy in April
    Motley Fool4 days ago

    3 Cancer Treatment Stocks to Buy in April

    These three cancer stocks have tremendous upside potential.

  • 5 Top Pharmaceutical Stocks to Buy in 2019
    Motley Fool5 days ago

    5 Top Pharmaceutical Stocks to Buy in 2019

    Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.

  • Business Wire7 days ago

    Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019

    – Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT –

  • ProQR Initiates Dosing in Phase II/III Eye Disorder Study
    Zacks8 days ago

    ProQR Initiates Dosing in Phase II/III Eye Disorder Study

    ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

  • Has Exelixis, Inc. (NASDAQ:EXEL) Got Enough Cash?
    Simply Wall St.9 days ago

    Has Exelixis, Inc. (NASDAQ:EXEL) Got Enough Cash?

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Exelixis, Inc. (NASDAQ:EXEL), with a market cap of US$7.0b, are often out of the spotlight. Despite this, commonly overlooked mid...

  • Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock
    InvestorPlace13 days ago

    Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock

    If you're asking whether or not to buy Exelixis (NASDAQ:EXEL) stock, the answer is, "it depends." But if you're a risk-tolerant investor in search of an up-and-coming biotech doing more than a few things right, it's time to consider buying EXEL stock. Let me explain.Source: Shutterstock If there is ever going to be a so-called perfect investment, you wouldn't expect it to be a smaller-capitalization biotechnology company like Exelixis. But that's really a generalization against a group of notoriously volatile stocks most investors need to think twice about before investing in. But that's not the situation with EXEL stock.The group as a whole has a backdrop of unstable financials, FDA approvals, the next drug trial finally being "the big one" or keeping larger competitors such as a Biogen (NASDAQ:BIIB) or Merck (NYSE:MRK) at bay. EXEL stock has defied those odds since mid-2016, when its kidney cancer blockbuster Cabometyx was approved.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAgain, that's not to say EXEL stock is the perfect investment. Bottom line, those types of risks don't simply vanish. But for now, this $7.2 billion market cap stock with its attractive forward P/E of 17.6, 0.5 PEG ratio and priced at 8.5x sales is in a strong position with the success of Cabometyx and sports a solid development pipeline which may just yet, make Exelixis a household name. EXEL Stock Weekly Price Chart Looking at the weekly chart of EXEL stock and despite some of the aforementioned volatility associated with smaller-cap biotechs, it's obvious Wall Street is also a buyer of what Exelixis has accomplished thus far -- and what appears to be a promising future. * 10 Dow Jones Stocks Holding the Blue Chip Index Back After a successful corrective challenge of prior lateral resistance and 62% retracement level from EXEL stock's 2015 low to 2018 cycle high last October, shares have been trending higher in the right side of a cup-shaped weekly base. That's bullish, and that's not all.Now and with EXEL consolidating the past month in-between the 50%-62% levels, a potential breakout and assault on the prior high of $32.50 before moving to new all-time-highs is setting up for purchasing. Buying EXEL StockFor investors agreeable with the risks discussed, the recommendation is to wait for a breakout. Without clearing the 62% retracement level, which has acted as price resistance thus far, there is a greater likelihood EXEL stock's uptrend could fail until proper price confirmation reveals itself.Not that a technical failure in this case is a bad thing. A turn lower in the share price of Exelixis could lead to an eventual double-bottom challenge. But I'd rather be a buyer of EXEL stock initiating a new position as it tests support than an investor long shares on the way down.Having said that, buying EXEL stock above $25.41 and 10 cents above last month's high within the consolidation pattern is the approach I'd use for entering into a long position. And again, as risks don't simply go away, a blended stop below $23.37 makes sense. This exit contains risk to 8% and allows for enough technical wiggle room while putting oneself in a stronger position to buy EXEL during potentially much more challenging and opportunistic times ahead.Investment accounts under Christopher Tyler's management do not currently own positions in any securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional options-based strategies, related musings or to ask a question, you can find and follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Best Dividend Stocks to Buy for Every Investor * 7 Catalysts That Will Send Marijuana Stocks Soaring in 2019 * 8 Risky Stocks to Watch as Earnings Season Kicks Off Compare Brokers The post Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock appeared first on InvestorPlace.

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Exelixis Inc.

    Exelixis Inc NASDAQ/NGS:EXELView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for EXEL with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding EXEL are favorable with net inflows of $72.95 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?
    Zacks19 days ago

    Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?

    Exelixis (EXEL) performance has been impressive so far in 2019 on the back of label expansion of Cabometyx.

  • Business Wire19 days ago

    Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019

    ̶ Presentation to be webcast on www.exelixis.com ̶

  • The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
    Zacks23 days ago

    The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

    The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

  • GlobeNewswire28 days ago

    Market Trends Toward New Normal in 3M, Exelixis, Wright Medical Group N.V, MSA Safety Incorporated, Principal Financial Group, and Portland General Electric — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Benzingalast month

    Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'

    Morgan Stanley has dropped its bearish stance on  Exelixis, Inc. (NASDAQ: EXEL ), although the research firm hasn't gained enough confidence to recommend buying the drugmaker's stock.  The Analyst Analyst ...

  • Signal Says Buy Options Insurance on This Biotech
    Schaeffer's Investment Researchlast month

    Signal Says Buy Options Insurance on This Biotech

    The shares are just off a new high, but could cool off soon, if history repeats

  • Exelixis (EXEL) Gains As Market Dips: What You Should Know
    Zackslast month

    Exelixis (EXEL) Gains As Market Dips: What You Should Know

    Exelixis (EXEL) closed at $24.76 in the latest trading session, marking a +0.2% move from the prior day.

  • American City Business Journalslast month

    How a biotech company navigated bay bureaucracy to set up a commuter ferry service

    The company took a crash course in trying to set up a transbay ferry service to get employees from South San Francisco to its new headquarters in Alameda.

  • Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report?
    Zackslast month

    Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report?

    Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.comlast month

    5 Biotech Stocks to Keep an Eye on in 2019

    The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).

  • Why Exelixis, Inc. (NASDAQ:EXEL) Is An Attractive Investment To Consider
    Simply Wall St.last month

    Why Exelixis, Inc. (NASDAQ:EXEL) Is An Attractive Investment To Consider

    Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Exelixis, Inc. (NASDAQ:EXEL) due to its excellent fundamentals in more thanRead More...

  • Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation
    Zackslast month

    Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation

    Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.

  • Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know
    Zacks2 months ago

    Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know

    Exelixis (EXEL) closed at $23.04 in the latest trading session, marking a -0.39% move from the prior day.

  • Business Wire2 months ago

    Exelixis Announces Webcasts of Investor Conference Presentations in March

    ̶ Presentations to be webcast on www.exelixis.com ̶